- Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus.
- Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average.
- A large short interest position and a number of analysts may be incorrectly banking on business growth to slip, assuming the coronavirus quickly disappears in the spring.
- The equity name represents a sound, risk-adjusted idea to speculate on and/or hedge a lingering pandemic during 2021.
For further details see:
Meridian Bioscience: Benefiting From A Prolonged Pandemic